<SEC-DOCUMENT>0001437749-24-032366.txt : 20241029
<SEC-HEADER>0001437749-24-032366.hdr.sgml : 20241029
<ACCEPTANCE-DATETIME>20241029081921
ACCESSION NUMBER:		0001437749-24-032366
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20241029
DATE AS OF CHANGE:		20241029

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NovaBay Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001389545
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				680454536
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33678
		FILM NUMBER:		241402759

	BUSINESS ADDRESS:	
		STREET 1:		2000 POWELL STREET, SUITE 1150
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
		BUSINESS PHONE:		(510) 899-8800

	MAIL ADDRESS:	
		STREET 1:		2000 POWELL STREET, SUITE 1150
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>nby20241029_defa14a.htm
<DESCRIPTION>FORM DEFA14A
<TEXT>
<html><head>
	<title>nby20240411_defa14a.htm</title>

	<!-- Created by RDG Portal --><meta charset="" utf-8""=""><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 10px; margin-left: 10px; cursor: auto;">
<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0">
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>UNITED STATES</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Washington, D.C. 20549</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 17pt; text-align: center;"><b>SCHEDULE 14A INFORMATION</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-align: center;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 17pt; text-align: center;"><b>Proxy Statement Pursuant to Section 14(a) of</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-align: center;"><b>the Securities Exchange Act of 1934</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-align: center;"><b>(Amendment No.</b>&nbsp;&nbsp;&nbsp;&nbsp;<b>)</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Filed by the Registrant &#9746;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Filed by a Party other than the Registrant&nbsp;&#9744;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Check the appropriate box:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9744;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Preliminary Proxy Statement</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9744;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9744;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Definitive Proxy Statement</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9746;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Definitive Additional Materials</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9744;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Soliciting Material Pursuant to &#167;&nbsp;240.14a-12</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;"><b>NOVABAY PHARMACEUTICALS, INC.</b></p>

<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">(Name of Registrant as Specified in Its Charter)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Payment of Filing Fee (Check the appropriate box):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9746;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">No fee required</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9744;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Fee paid previously with preliminary materials</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9744;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNITED STATES</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>FORM 8-K</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CURRENT REPORT</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Pursuant to Section 13 or 15(d) of the</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Securities Exchange Act of 1934</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date of earliest event reported:</b> October 29, 2024</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td colspan="3" style="vertical-align: top; width: 66%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">NovaBay Pharmaceuticals, Inc.</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Exact Name of Registrant as Specified in Charter)</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Delaware</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(State of Other Jurisdiction of Incorporation)</b></p>
			</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">001-33678</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Commission File Number)</b></p>
			</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">68-0454536</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(I.R.S. Employer Identification No.)</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td colspan="3" style="vertical-align: top; width: 66%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2000 Powell Street, Suite 1150,&nbsp;Emeryville,&nbsp;CA&nbsp;94608</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Address of Principal Executive Offices) (Zip Code)</b></p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align: top; width: 66%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td colspan="3" style="vertical-align: top; width: 66%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(510)&nbsp;899-8800</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Registrant</b>&#8217;<b>s telephone number, including area code)</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9744;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9744;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9744;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9744;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 33.7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><u>Title of Each Class</u></b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Common Stock, par value $0.01 per share</p>
			</td>
			<td style="vertical-align: top; width: 33.7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><u>Trading Symbol(s)</u></b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">NBY</p>
			</td>
			<td style="vertical-align: top; width: 33.7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><u>Name of Each Exchange On Which Registered</u></b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">NYSE American</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter). Emerging growth company&nbsp;&#9744;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&#9744;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 8.01</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Other Events.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As previously disclosed, on September 19, 2024, NovaBay Pharmaceuticals, Inc. (the &#8220;Company&#8221;) entered into an Asset Purchase Agreement (the &#8220;PRN APA&#8221;) with PRN Physician Recommended Nutriceuticals, LLC (&#8220;PRN&#8221;), pursuant to which the Company would sell all of its eyecare products sold under the Avenova brand and the related assets (the &#8220;Avenova Assets&#8221;) to PRN, subject to meeting certain closing conditions including receiving stockholder approval (the &#8220;PRN Transaction&#8221;). Additional information regarding the PRN Transaction and the PRN APA is included in the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on September 20, 2024 and in the Company&#8217;s definitive proxy statement on Schedule 14A for a special meeting of the Company&#8217;s stockholders (the &#8220;Special Meeting&#8221;) filed with the SEC on October 16, 2024 (the &#8220;Special Meeting Proxy Statement&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On October 29, 2024, the Company announced that its Board of Directors (the &#8220;Board&#8221;) determined that an unsolicited and non-binding acquisition proposal from Refresh Acquisitions BidCo LLC (&#8220;Refresh&#8221;) to purchase the Avenova Assets (the &#8220;Refresh Unsolicited Offer&#8221;) is a &#8220;Superior Proposal&#8221; (as defined in the PRN APA). As a result, the Company notified PRN of the Board&#8217;s determination and the Company&#8217;s intention to terminate the PRN APA pursuant to its terms, unless the Company receives a revised proposal from PRN by 11:59 p.m. Pacific Time on November 4, 2024 such that the Board determines the Refresh Unsolicited Offer is no longer a Superior Proposal, all in accordance with the process provided in the PRN APA.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Refresh Unsolicited Offer provides for terms that are substantially similar to the PRN Transaction, except that the Company would receive a base purchase price of $11.5 million (as compared to $9.5 million in the PRN APA), subject to a downside net working capital adjustment. The Refresh Unsolicited Offer also includes Refresh providing a secured term loan to the Company in the principal amount of $2.0 million, with an interest rate of 10.0% per annum (the &#8220;Secured Loan&#8221;) in connection with entering into a transaction with Refresh, which is expected to be repaid upon closing and deducted from the purchase price. The Secured Loan would continue to be outstanding until the earlier to occur of a transaction with Refresh closing or a purchase agreement with Refresh being terminated.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Notwithstanding the Refresh Unsolicited Offer and the Board determination, in accordance with the PRN APA process, the PRN APA remains in full force and effect, and the Board has not withdrawn or modified its recommendation regarding the pending PRN Transaction as disclosed in the Special Meeting Proxy Statement, to allow for the 5-day review period by PRN and opportunity to provide a counteroffer during such time.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">A copy of the press release issued by the Company is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Additional Information and Where to Find It</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">In connection with the solicitation of proxies, on October 16, 2024, the Company filed the Special Meeting Proxy Statement with the SEC with respect to the Special Meeting in connection with the PRN Transaction and a potential voluntary liquidation and dissolution of the Company (the &#8220;Dissolution&#8221;). Promptly after filing the Special Meeting Proxy Statement with the SEC, the Company mailed the Special Meeting Proxy Statement and a proxy card to each stockholder entitled to vote at the Special Meeting to consider the PRN Transaction and the Dissolution. STOCKHOLDERS ARE URGED TO READ THE SPECIAL MEETING PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS, INCLUDING IN CONNECTION WITH THE PRN TRANSACTION AND THE DISSOLUTION, THAT THE COMPANY HAS FILED WITH THE SEC BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY, THE PRN TRANSACTION AND THE DISSOLUTION. Stockholders may obtain, free of charge, the Special Meeting Proxy Statement, any amendments or supplements thereto, and any other relevant documents filed by the Company with the SEC in connection with the PRN Transaction and the Dissolution at the SEC&#8217;s website (http://www.sec.gov) or at the Company&#8217;s investor relations website (https://novabay.com/investors/) or by writing to NovaBay Pharmaceuticals, Inc., Investor Relations, 2000 Powell Street, Suite 1150, Emeryville, CA 94608. Our website address is provided as an inactive textual reference only. The information provided on, or accessible through, our website is not part of this Current Report on Form 8-K, and, therefore, is not incorporated herein by reference.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Participants in the Solicitation</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the Company&#8217;s stockholders in connection with the proposed PRN Transaction and the proposed Dissolution. A list of the names of the directors and executive officers of the Company and information regarding their interests in the PRN Transaction and the Dissolution, including their respective ownership of the Company&#8217;s common stock and other securities is contained in the Special Meeting Proxy Statement for the proposed PRN Transaction and the proposed Dissolution. In addition, information about the Company&#8217;s directors and executive officers and their ownership in the Company is set forth in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and filed with the SEC on March 26, 2024, as amended on March 29, 2024 and as modified or supplemented by any Form 3 or Form 4 filed with the SEC since the date of such filing.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Cautionary Language Concerning Forward-Looking Statements</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>This Current Report on Form 8-K contains forward-looking statements within the meaning of the </i>&#8220;<i>safe harbor</i>&#8221;<i> provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. These forward-looking statements are based upon the Company and its management</i>&#8217;<i>s current expectations, assumptions, estimates, projections and beliefs. Such statements include, but are not limited to, statements regarding the PRN Transaction, the Refresh Unsolicited Offer, the Dissolution and related matters such as the impact of the PRN Transaction and the Refresh Unsolicited Offer on the Company. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in, or implied by, these forward-looking statements. Other risks relating to the Company</i>&#8217;<i>s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this Current Report, are detailed in the Company</i>&#8217;<i>s latest Form 10-K, subsequent Forms 10-Q and/or Form 8-K filings with the SEC and</i> <i>the Special Meeting Proxy Statement, especially under the heading </i>&#8220;<i>Risk Factors.</i>&#8221;<i> The forward-looking statements speak only as of this date, and the Company disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 9.01</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Financial Statements and Exhibits.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Exhibits</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exhibit No.</p>
			</td>
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 81%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Description</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">99.1</p>
			</td>
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 81%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="ex_739267.htm" style="-sec-extract:exhibit;">Press Release dated as of October 29, 2024</a></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">104</p>
			</td>
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 81%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SIGNATURES</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td colspan="2" valign="top" width="38%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>NovaBay Pharmaceuticals, Inc.</b><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" valign="bottom" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td align="left" style="text-align: left;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="text-align: left" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">By: </font></p>
			</td>
			<td align="left" nowrap="nowrap" style="BORDER-BOTTOM: #000000 1px solid" valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">/s/&nbsp;</font>Justin M. Hall</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Justin M. Hall<font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Chief Executive Officer and General Counsel<font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 216pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 216pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dated: October 29, 2024</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_739267.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_739267.htm</title>

	<!-- Generated by ThunderDome Portal - 10/29/2024 12:06:04 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 99.1</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><img alt="nb01.jpg" src="nb01.jpg"></div>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NovaBay Pharmaceuticals Board Determines Unsolicited Offer is Superior to Asset Purchase Agreement with PRN Physician Recommended Nutriceuticals, LLC</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>EMERYVILLE, Calif. (October 29, 2024)</b> &#8211; <u>NovaBay&#174; Pharmaceuticals, Inc</u>. (NYSE American: NBY) (&#8220;NovaBay&#8221; or the &#8220;Company&#8221;) announces that the Company&#8217;s board of directors has determined that an unsolicited and non-binding offer from Refresh Acquisitions BidCo LLC (&#8220;Refresh&#8221;) for an affiliate of Refresh to acquire the Company&#8217;s Avenova&#174; brand and related assets is a &#8220;Superior Proposal&#8221; to the Company&#8217;s asset purchase agreement with PRN Physician Recommended Nutriceuticals, LLC (&#8220;PRN&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Refresh&#8217;s unsolicited offer provides for terms that are substantially similar to the contemplated transaction with PRN, except that the Company would receive a purchase price of up to $11.5 million (compared with $9.5 million in the transaction with PRN), subject to a downside net working capital adjustment. Refresh&#8217;s unsolicited offer also includes Refresh providing a secured term loan to the Company in the principal amount of $2.0 million, which is expected to be repaid upon closing and deducted from the purchase price.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company has notified PRN of the board of directors&#8217; determination and that the Company intends to terminate its asset purchase agreement with PRN unless the Company receives a revised proposal from PRN by 11:59 p.m. Pacific time on November 4, 2024, such that the Company&#8217;s board of directors determines that Refresh&#8217;s unsolicited offer is no longer a Superior Proposal, in accordance with the process provided in the asset purchase agreement with PRN.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8220;After careful consideration, our board of directors determined that the unsolicited offer by Refresh represents greater value for our stockholders while also placing Avenova in highly capable commercial hands,&#8221; said Justin Hall, NovaBay CEO. &#8220;Refresh is an affiliate company of RVL Pharmaceuticals, which is commercializing Upneeq&#174;<sup style="vertical-align:top;line-height:120%;"> </sup>(oxymetazoline hydrochloride ophthalmic solution), 0.1%, the first and only FDA-approved prescription eye drops for adults with low-lying eyelids, also known as acquired blepharoptosis or ptosis. Our Avenova products are highly complementary to this non-surgical solution that quickly lifts eyelids for more awake-looking eyes. Further, RVL Pharmaceuticals and NovaBay are aligned in our shared passion for commercializing products that improve patients&#8217; lives.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company&#8217;s asset purchase agreement with PRN, in accordance with such agreement, remains in full force and effect, and the Company&#8217;s board of directors has not withdrawn or modified its recommendation regarding stockholders approving the pending transaction with PRN. The Company&#8217;s transaction with PRN remains subject to certain closing conditions, including receiving stockholder approval.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Consistent with its fiduciary duties, the Company&#8217;s board of directors conducted a comprehensive evaluation of the Refresh unsolicited offer with assistance from independent financial and legal advisors, before making its determination.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>About NovaBay Pharmaceuticals, Inc.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">NovaBay's leading product Avenova&#174; Lid &amp; Lash Cleansing Spray is often recommended by eyecare professionals for blepharitis and dry eye disease. Manufactured in the U.S., Avenova spray is formulated with NovaBay's patented, proprietary, stable and pure form of hypochlorous acid. All Avenova products are available directly to consumers through online distribution channels such as <u>Amazon.com</u> and <u>Avenova.com</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Forward-Looking Statements</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. These forward-looking statements are based upon the Company and its management&#8217;s current expectations, assumptions, estimates, projections and beliefs. Such statements include, but are not limited to, statements regarding the contemplated transaction with PRN, the unsolicited offer by Refresh and related matters. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in, or implied by, these forward-looking statements. Other risks relating to NovaBay's business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in the Company's latest Form 10-K, subsequent Forms 10-Q and/or Form 8-K filings with the Securities and Exchange Commission (the &#8220;SEC&#8221;) and the Special Meeting Proxy Statement (as defined below), especially under the heading "Risk Factors." The forward-looking statements in this release speak only as of this date, and the Company disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Additional Information and Where to Find It</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In connection with the solicitation of proxies, on October 16, 2024, NovaBay filed a definitive proxy statement with the SEC with respect to the special meeting to be held in connection with the proposed asset sale to PRN and a potential voluntary liquidation and dissolution of the Company (the &#8220;Special Meeting Proxy Statement&#8221;). Promptly after filing the Special Meeting Proxy Statement with the SEC, NovaBay mailed the Special Meeting Proxy Statement and a proxy card to each stockholder entitled to vote at the special meeting to consider the contemplated asset sale to PRN and potential dissolution. STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT NOVABAY HAS FILED OR WILL FILE WITH THE SEC BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Stockholders may obtain, free of charge, the Special Meeting Proxy Statement, any amendments or supplements thereto, and any other relevant documents filed by NovaBay with the SEC in connection with the contemplated asset sale to PRN and potential dissolution at the SEC's website (http://www.sec.gov) or at the Company&#8217;s investor relations website https://novabay.com/investors/) or by writing to NovaBay Pharmaceuticals, Inc., Investor Relations, 2000 Powell Street, Suite 1150, Emeryville, CA 94608. The information provided on, or accessible through, our website is not part of this communication, and therefore is not incorporated herein by reference.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Participants in the Solicitation</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">NovaBay and its directors and executive officers may be deemed to be participants in the solicitation of proxies from NovaBay's stockholders in connection with the contemplated asset sale to PRN and the potential dissolution. A list of the names of the directors and executive officers of the Company and information regarding their interests in the contemplated asset sale to PRN and the potential dissolution, including their respective ownership of the Company&#8217;s common stock and other securities is contained in the Special Meeting Proxy Statement. In addition, information about the Company&#8217;s directors and executive officers and their ownership in the Company is set forth in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and filed with the SEC on March 26, 2024, as amended on March 29, 2024 and as modified or supplemented by any Form 3 or Form 4 filed with the SEC since the date of such filing.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><u>Socialize and Stay Informed on NovaBay</u></b><u>&#8217;</u><b><u>s Progress </u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Like us on <u>Facebook</u></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Follow us on <u>X</u></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Connect with NovaBay on <u>LinkedIn</u></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Visit NovaBay&#8217;s <u>Website</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><u>Avenova Purchasing Information </u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For NovaBay Avenova purchasing information:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Please call 800-890-0329 or email sales@avenova.com</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Avenova.com</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><u>NovaBay Contact </u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Justin Hall</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Chief Executive Officer and General Counsel</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">510-899-8800</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">jhall@novabay.com</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><u>Investor Contact </u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Alliance Advisors IR</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Jody Cain</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">310-691-7100</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">jcain@allianceadvisors.com</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"># # #</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>nb01.jpg
<TEXT>
begin 644 nb01.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M$E%(6 HW<5F= M%&:3=S0 M%(&!I<B@ HHSS2 YH"XM(6 ZD8H9L5Y/^U?\
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MFSY);KHT?L]_P=,';^S)\+^A4^*G/L?]%>OQ/<!83QVK]'/^"I7_  4!TO\
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M=T*MM>J\GZ'G4LZQ-3#UJ,;>WI7NNCMU1D/_ ,')O[-RQEO/\:C'7_B1O_\
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ML$NO,\K=LQN^[C<>GK7Z[CWBOJ[^I6Y_/8_&\MCA777UV_)Y;GL3_P#! _\
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MKU<#PQE.94I3PZE"W?\ X)Y..XJSK+*T:>)G&=]=/\S^HW]L;]N7PO\ L6?
M2+XD:WI^L>(/#,ES!;O/HD:71B6;_5S'Y@#&3@;@>K"ODK_B)V^!0&#X;^(F
M?;3H_P#XY7&?\$/+67]N'_@E;\2OA!XOG>_TO3+N?0K&29B[6L$T*RQ $_\
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MW/P\\52277AR].6$/.7LW;^_'V)^\N#V-?6__!K#;2VWQ'^,7FPSQ9T_3O\
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M)J.OZ.R?:+K3-#L/L6G%8\MON)!QM&,X9L$XX-?([:;=)*RFTO T;E&_T=\
M@X/;VJ<BGBHQE''U(N>FBMHB\^AAIRC++Z4E"V[N[L_:3_@UD7_C'GXK=_\
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MZ>>AY;\6/' ^)WQ3\3^)EL(-+7Q%JMSJ2V<(PEJLLK.$'T!K['_X-^OV3?\
MAHK]NBU\3W]L)_#_ ,+H!K$I=<H]Z^4MD/N#O?\ X *^1O!7P$\>?$O78-+\
M.^"/%NL:C=,(XX+;2IV+L>V=NT?4D"OZ%/\ @C3^P1<_L&?LG0:7K\=N/''B
MFX_M;7S$=RP2%0L=N&[B- !D<;BV*_0>*\XHX7+OJ]&5Y/3>[MW/SGA#)JV,
MS-8BM%J,?>>G7L?6T"$#=ZU*!BD P32U^+)'[N%%%%, HHHH **** "BBB@
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
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
